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Abstract
Background: Development of acute kidney injury (AKI) after out-of-hospital cardiac
arrest (OHCA) is associated with mortality and poor neurological outcome. However,
the effect of recovery from AKI after OHCA is uncertain. This study investigates
whether recovery from AKI was associated with the rate of survival and neurological
outcome at 30 days after OHCA.
Methods: This is a prospective multicentre observational cohort study of adult OHCA
patients treated with targeted temperature management (TTM) across five hospitals in
South Korea between February 2019 and July 2020. AKI was diagnosed using the
Kidney Disease: Improving Global Outcomes criteria. The primary outcome was the
rate of survival at 30 days, and the secondary outcome was the rate of survival with
a favourable neurological outcome at 30 days, defined by a score of 3 or less on the
modified Rankin scale.
Results: Among the 2,018 patients with OHCA, 79 were treated with TTM. After
excluding two patients with incomplete data on outcomes, 77 were analysed. AKI
developed in 43 (56%) patients. Among them, 22 (51%) recovered from AKI. Although
the rate of survival at 30 days for the recovery group was superior to the non-recovery
group (82% vs. 24%, P < 0.001), the rate of survival with a favourable neurological
outcome at 30 days for the recovery groupwas not different than that for the non-recovery
group (32% vs. 10%, P = 0.132). Recovery from AKI was an independent predictor of
survival at 30 days after OHCA in the multivariate analysis (adjusted odds ratio, 22.737;
95% confidence interval, 3.814-135.533; P = 0.001); however, it was not associated with
a favourable neurological outcome at 30 days after OHCA in the multivariate analysis.
Conclusion: Recovery from AKI was an independent predictor of survival at 30 days
only after OHCA who were treated by TTM.
Keywords
Acute kidney injury; Out-of-hospital cardiac arrest; Targeted temperature management;
Therapeutic hypothermia
1. Introduction
Acute kidney injury (AKI) is associated with increased risk
of death and poor neurological outcome after out-of-hospital
cardiac arrest (OHCA) [1, 2]. Because AKI has been con-
firmed as a risk factor of mortality, recovery from AKI might
be associated with a good outcome. In case of critically
ill patients, the rate of survival of patients who recovered
from AKI was significantly higher than those who did not
recover [3]. However, the effect of recovery from AKI after
OHCA is uncertain. Although one retrospective cohort study
reported that the recovery from AKI was a potent predictor
of survival and good neurological outcome at discharge, there
were several limitations to the study, including that the de-
velopment of AKI and recovery from AKI were determined
retrospectively and the outcomes could not be determined at
the same time point among the patients [4]. To address these
limitations, our prospective cohort study aims to identify the
effect of recovery from AKI on the rate of survival and good
neurological outcome at 30 days after OHCA.We hypothesised
that the rate of survival at 30 days after OHCA in patients who
recovered from AKI was superior to the patients who did not
recover from AKI.
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2. Materials and methods
2.1 Study design and setting
This is a prospective multicentre observational cohort study.
Data were collected from five academic hospitals in South Ko-
rea between February 2019 and July 2020. The development
of AKI and recovery from AKI were defined prospectively
considering both the serum creatinine level and hourly urine
output. The study design and plan, including the informed
consent form, were approved by the institutional review board
of each hospital and were registered at the International Clin-
ical Trials Registry Platform (Clinical Research Information
Service; Korea Centers for Disease Control and Prevention,
Ministry of Health and Welfare, Osong, Chungcheongbuk-do,
Republic of Korea, (https://cris.nih.go.kr [registered
No. KCT0003544])) on February 21, 2019. The first partici-
pant was enrolled on March 18, 2019, and the last participant
was enrolled on July 22, 2020.
2.2 Study population
All adult patients with OHCA irrespective of the cause of
arrest who were unconscious after the return of spontaneous
circulation (ROSC) and treated with targeted temperatureman-
agement (TTM) were enrolled in the registry. Patients aged <
19 years, those who were dead on arrival to the hospital and did
not receive cardiopulmonary resuscitation (CPR), those who
did not achieve ROSC despite cardiopulmonary resuscitation,
those who did not receive TTM despite achieving ROSC,
those diagnosed with end-stage renal disease with dialysis
(peritoneal dialysis or haemodialysis) before developing car-
diac arrest, those who had a Do-Not-Attempt-Resuscitation
(DNAR) order, those who had acute intracranial haemorrhage
or acute ischaemic stroke, and those who had active bleeding
were excluded. In addition, patients were excluded from the
study when patients’ legal surrogates refused to participate or
withdrew informed consent during the study period. Enrolled
patients received care for post-cardiac arrest syndrome accord-
ing to the standard operating procedures for OHCAat each hos-
pital. The principal investigator of each participating hospital
collected data from the hospital records of OHCA survivors
treated with TTM and determined the development of AKI and
recovery from AKI prospectively. The independent data input
researcher investigated survival status and modified Rankin
scale (MRS) at 30 days after OHCA. If patients died before
30 days, the death date was recorded.
2.3 Indication and contraindication of TTM
Regardless of the initial rhythm, patients who did not show
meaningful responses to verbal commands after ROSC for
more than 20 minutes were treated with TTM. Cardiac arrest
associated with trauma, severe sepsis, having poor cognition
or poor neurological condition before cardiac arrest, preg-
nancy, arrhythmia not responding to treatment or coronary
vasospasm, refractory shock not responding to fluid or vaso-
pressors, active bleeding or thrombolytic use, and therapeutic
hypothermia were relatively contraindicated; thus, TTM could
be decided by the institution’s expert. However, TTM was
contraindicated for patients with terminal illness before cardiac
arrest, those who had a DNAR order, and those with other
aetiologies for coma.
2.4 Definition of AKI
The development and staging of AKI were defined using the
Kidney Disease: Improving Global Outcomes criteria [5].
AKI was defined when one of the following conditions were
fulfilled. First, an increase in serum creatinine more than 1.5
times baseline within 7 days after OHCA. Second, an increase
in serum creatinine more than 0.3 mg/dL within 48 hours.
Third, a decrease in hourly urine output lower than 0.5mL/kg/h
for 6 hours. The baseline serum creatinine was defined as the
last available serum creatinine level within the last 3 months.
If the last available serum creatinine level within the last 3
months was unknown, the baseline serum creatinine level was
defined as the lowest value between the post-ROSC value
and estimated serum creatinine value through the use of the
Modification of Diet in Renal Disease equation [5]. Recovery
from AKI was defined when all the AKI criteria were not
fulfilled (decrease in the serum creatinine level within 150%
of the baseline serum creatinine level without oliguria [hourly
urine output ≥ 0.5 mL/kg/h for 6 h]).
2.5 Variables
The primary outcome was the rate of survival at 30 days,
and the secondary outcome was the rate of survival with a
favourable neurological outcome at 30 days, which was de-
fined by a score of 3 or less on the MRS. Other variables were
as follows: age (years), sex (male or female), weight (kg),
past medical history (hypertension, diabetes mellitus, heart
failure), witnessed cardiac arrest (witnessed or not witnessed),
bystander CPR (yes or no), first monitored rhythm (shockable
or non-shockable), CPR time (min), epinephrine dose (mg),
coronary angiography (yes or no), extracorporeal membrane
oxygenation (yes or no), urine output (mL/kg/h) in the inten-
sive care unit, event of shock (mean arterial pressure < 70
mmHg) after OHCA, daily serum creatinine level (mg/dL),
renal replacement therapy (yes or no), survival status at 30
days after OHCA, MRS at 30 days after OHCA, and the date
of death if the patient died within 30 days after OHCA. If
the serum creatinine level was checked two or more times a
day, the highest value was recorded. All dates were calculated
from the day of the OHCA. The MRS was used for assessing
neurological outcomes, with an MRS of 0-3 considered as a
good outcome and an MRS of 4-6 as a poor outcome [6].
The MRS was calculated using a 9-question telephone survey
(modifiedrankin.com) [7]. The telephone survey was per-
formed by independent data input researcher.
2.6 Sample size
The sample size was calculated on the basis of relative risk
precision using the relative risk of survival rate for the AKI
recovery group. Although the primary outcome was the rate
of survival at 30 days, no other studies have reported a cohort
of AKI recovery group after OHCAwith a rate of survival at 30
days prior to the start of this study. Therefore, the relative risk
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of the rate of survival at discharge for the AKI recovery group
was used for calculating the sample size. A previous study
reported that the proportion of the AKI non-recovery group and
the relative risk of survival at discharge for the AKI recovery
group were 0.61 and 4, respectively [4]. The probability of
type I error was set at 0.05, and the relative risk precision was
set at 10%. Using these parameters, a web-based sample size
calculator estimated a minimum sample size of 18 for each
group [8]. Therefore, 36 patients with AKI after OHCAwould
be needed.
2.7 Statistical methods
Descriptive statistics were reported as median (interquartile
range) or mean ± standard deviation for continuous variables
according to the normality of distribution. Data normality was
analysed using the Shapiro-Wilk test or Kolmogorov-Smirnov
test. Categorical variables were reported as frequency (per-
centage). Demographics and clinical differences between the
groupswere assessed using Pearson’s chi-squared test, Fisher’s
exact test, independent sample t-test, or Mann-Whitney U
test, as appropriate. The association between predictors and
outcome was quantified using the odds ratio (OR) with 95%
confidence interval (CI). To determine the independent factors
associated with the outcomes, the multivariate logistic regres-
sion analysis was performed, which included all variables with
a P-value of < 0.2; a stepwise backward selection of the
variables was then applied, which remained significant. The
Hosmer-Lemeshow test was used for evaluating the goodness
of fit of the logistic regression model. Differences in the
Kaplan-Meier survival curves between the groups (non-AKI
group vs. AKI group and AKI recovery group vs. AKI
non-recovery group) were compared using the log-rank test.
A P-value of < 0.05 was considered statistically significant.
Statistical analyses were performed using IBM SPSS version
25.0 (IBM Corp., Armonk, NY, USA).
3. Results
3.1 Study population
Of the 2,018 patients with OHCA screened during the study
period, 79 were treated with TTM at five academic hospitals
(Fig. 1). After excluding two patients with incomplete data
on outcomes, 77 were analysed. The baseline characteristics
of the patients according to AKI and recovery status from AKI
are summarised in Table 1.
3.2 Descriptive data
Themean age of the patients was 58± 16 years, and their mean
weight was 68 ± 12 kg, with most patients being men (56/77,
73%). The median duration of CPR was 26± 18 mins, and the
median dose of adrenaline (epinephrine) was 1 mg (0-4 mg).
The baseline serum creatinine was 1.00 (1.00-1.10) mg/dL.
3.3 Clinical course of AKI
AKI developed in 43/77 (56%) patients, and 22/43 (51%)
recovered from AKI. In total, 35/43 (81%) patients were di-
agnosed with AKI based on serum creatinine level, and 8/43
(19%) were diagnosed on the basis of the hourly urine output
criteria. In all the cases, AKI developed within 3 days since
ROSC (29/43 [68%] on day 1, 7/43 [16%] on day 2, and 7/43
[16%] on day 3). Renal recovery occurred in 6 (3-7) days
after OHCA, and the median duration of AKI was 4 (2-10)
days. The duration of AKI was significantly longer for the
AKI non-recovery group than for the AKI recovery group (7
[3-13] vs. 4 [2-6] days; P = 0.02). The distribution of AKI
stages was as follows: stage 1, 18/43 (42%); stage 2, 7/43
(16%); and stage 3, 18/43 (42%). The recovery rate from AKI
was significantly different among the stages of AKI (14/18
[78%] in stage 1, 5/7 [71%] in stage 2, 3/18 [17%] in stage
3, P < 0.001) (Fig. 2). Renal replacement therapy (RRT)
was conducted in 14/43 (33%) patients. The most common
modality of RRT was continuous renal replacement therapy
(13/14 [93%]). The median duration of RRT was 9 ± 6 days.
There were no differences in the duration of RRT according
to renal recovery (10 ± 8 days in recovery group vs. 9 ± 6
days in non-recovery group, P = 0.787). None of the RRT
patients required RRT at 30 days after ROSC. Among 14 RRT
patients, eight expired, three recovered from AKI, two stopped
RRT bywithdrawing life sustaining therapy, and one converted
to chronic kidney disease.
3.4 Rate of survival at 30 days after OHCA
In total, 51/77 (66%) patients survived at 30 days after OHCA.
The rate of survival at 30 days after OHCA for the non-AKI
group was significantly higher than that for the AKI group
(28/34 [82%] vs. 23/43 [54%], P = 0.008); the rate of survival
was significantly different according to the stages of AKI
(14/18 [78%] in stage 1, 3/7 [43%] in stage 2, and 6/18 [33%]
in stage 3, P = 0.008) (Fig. 3). For the AKI group, the rate
of survival at 30 days after OHCA for the recovery group was
significantly higher than that for the non-recovery group (18/22
[82%] vs. 5/21 [24%], P < 0.001). Recovery from AKI and
shock were independent predictors of survival at 30 days after
OHCA in patients with AKI (recovery from AKI: adjusted OR
22.737, 95%CI 3.814-135.533, P = 0.001; shock: adjusted OR
0.112, 95%CI 0.015-0.807, P = 0.030; Hosmer and Lemeshow
test: chi-square = 0.366; df = 2; P = 0.833).
3.5 Survival analysis
The Kaplan-Meier survival curves differed significantly be-
tween the non-AKI and AKI groups (P = 0.006) (Fig. 4).
In the AKI group, the Kaplan-Meier survival curves differed
significantly between the recovery and non-recovery groups (P
< 0.001) (Fig. 5). However, there was no difference between
the non-AKI and AKI recovery groups (P = 0.99) (Fig. 5).
3.6 Favourable neurological outcome at 30
days after OHCA
The distribution of MRS at 30 days after OHCA according to
the group are summarised in Table 2. In total, 32/77 (42%)
patients had a score of 3 or less on the MRS at 30 days after
OHCA. The rate of favourable neurological outcome at 30 days
after OHCA for the non-AKI group was significantly higher
than that for the AKI group (23/34 [68%] vs. 9/43 [21%],
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FIGURE 1. Study flow diagram. AKI, acute kidney injury; OHCA, out-of-hospital cardiac arrest; MRS, modified Rankin
scale; TTM, targeted temperature management.
FIGURE 2. Recovery rate from different stages of acute
kidney injury. AKI, acute kidney injury.
P < 0.001), and the rate of favourable neurological outcome
was significantly different according to the stages of AKI (8/18
[44%] in stage 1, 0/7 [0%] in stage 2, and 1/18 [6%] in stage
3, P = 0.005). For the AKI group, the rate of favourable
neurological outcome at 30 days after OHCA for the recovery
FIGURE 3. Rate of survival at 30 days for different
stages of acute kidney injury. AKI, acute kidney injury.
group was not different than that for the non-recovery group
(7/22 [32%] vs. 2/21 [10%], P = 0.13) (Fig. 6). There were no
independent predictors of favourable neurological outcome at
30 days after OHCA in patients with AKI.
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TABLE 1. Baseline characteristics according to the groups
Variables Non-AKI group (n = 34) AKI group (n = 43) P value
AKI recovery group (n = 22) AKI non-recovery group (n = 21)
Demographics
Male sex 20 (59) 18 (82) 18 (86) 0.02
Age (years) 52 ± 16 61 ± 15 62 ± 14 0.04
Weight (kg) 66 ± 14 69 ± 8 71 ± 13 0.27
Medical history
Hypertension 14 (41) 11 (50) 8 (38) 0.71
Diabetes mellitus 4 (12) 8 (36) 7 (33) 0.05
Heart failure 2 (6) 2 (9) 1 (5) 0.93
Baseline sCr (mg/dL) 1.10 (0.90-1.10) 1.00 (1.00-1.10) 1.00 (1.00-1.10) 0.76
Resuscitation
Witnessed arrest 23 (68) 18 (82) 15 (71) 0.66
Bystander CPR 20 (61) 14 (64) 16 (76) 0.49
Shockable rhythm 19 (70) 7 (37) 3 (18) < 0.001
CPR time (min) 20 (9-30) 30 (19-38) 37 (17-40) 0.004
Epinephrine dose (mg) 0 (0-3) 2 (0-4) 3 (1-6) 0.03
Post-resuscitation
TT of 33 ◦C 23 (32) 4 (18) 11 (52) 0.204
TT of 36 ◦C 11 (68) 18 (82) 10 (48) 0.204
TTM of 24-hour 27 (79) 20 (91) 14 (67) 0.363
TTM of 48-hour 7 (20) 2 (9) 7 (33) 0.363
Shock 21 (62) 15 (68) 15 (71) 0.74
Coronary angiography 19 (56) 8 (36) 4 (19) 0.01
ECMO 0 (0) 0 (0) 2 (5) 0.16
AKI stage < 0.001
Stage 1 N/A 14 (64) 4 (19)
Stage 2 N/A 5 (23) 2 (10)
Stage 3 N/A 3 (14) 15 (71)
CRRT N/A 2 (9) 11 (52) < 0.001
Outcome
Survival at 30 days 28 (82) 18 (82) 5 (24) < 0.001
Good MRS (0 to 3) at 30 days 23 (68) 7 (32) 2 (10) < 0.001
Values are expressed as number (%) or mean ± standard deviation (or median [interquartile range]).
P < 0.05 are presented in bold.
AKI, acute kidney injury; CPR, cardiopulmonary resuscitation; CRRT, continuous renal replacement therapy; ECMO,
extracorporeal membrane oxygenation; MRS, modified Rankin scale; N/A, not applicable; sCr, serum creatinine; TT, targeted
temperature; TTM, targeted temperature management.
TABLE 2. Modified Rankin scales at 30 days after cardiac arrest according to the groups
Modified Rankin Scale Total (n = 77) Non-AKI group (n = 34) AKI group (n = 43)
AKI recovery group (n = 22) AKI non-recovery group (n = 21)
1 17 (22) 12 (35) 4 (18) 1 (5)
2 11 (14) 9 (26) 2 (9) 0 (0)
3 4 (5) 2 (6) 1 (5) 1 (5)
4 3 (4) 2 (6) 1 (5) 0 (0)
5 15 (19) 3 (9) 10 (45) 2 (10)
6 27 (35) 6 (18) 4 (18) 17 (81)
Values are expressed as number (%).
4. Discussion
In this prospective multicentre observational cohort study, we
found that recovery from AKI was an independent predictor
of survival at 30 days after OHCA. However, it was not
associated with a favourable neurological outcome at 30 days
after OHCA. Although brain injury has been identified as the
leading cause of death after OHCA, AKI is a well-known risk
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FIGURE 4. Thirty-day cumulative survival for patients with or without acute kidney injury after out-of-hospital cardiac
arrest. AKI, acute kidney injury; OHCA, out-of-hospital cardiac arrest.
FIGURE 5. Thirty-day cumulative survival according to recovery status from acute kidney injury after out-of-hospital
cardiac arrest. AKI, acute kidney injury; OHCA, out-of-hospital cardiac arrest.
factor for mortality in critically ill patients, including those
with post-cardiac arrest [9–15]. Even mild reversible AKI,
such as stage 1 AKI, could increase the risk of death [2, 5, 11].
In the epidemiologic studies of critically ill patients, the rate
of recovery after AKI was markedly higher for survivors, and
the rate of survival was significantly higher for the group of
recovery after AKI [3, 16]. Therefore, maximising recovery of
renal function is the goal of any AKI prevention and treatment
strategy in the critical care area [17].
In our cohort, recovery from AKI played an important role
in improving patients’ outcome. Considering the results of
previous retrospective study, it was expected that the rate of
survival would be higher for the AKI recovery group than for
the AKI non-recovery group [4]. We could not expect that
the rate of survival for the AKI recovery group was similar
to that for the non-AKI group because even stage 1 AKI could
increase mortality. However, the rate of survival at 30 days
after OHCA for the AKI recovery group was not different than
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FIGURE 6. Differences of outcomes among the groups.
AKI, acute kidney injury.
that for the non-AKI group (P = 1.00) (Fig. 6). In addition,
there were no differences in the Kaplan-Meier survival curves
between the non-AKI group and AKI recovery group (Fig.
5). These unexpected results suggested that renal recovery
could be a treatment target for improving the rate of survival
after OHCA. Furthermore, renal recovery could be used as a
survival predictor when AKI develops after OHCA.
However, the rate of favourable neurological outcome at 30
days after OHCA for the AKI recovery group was significantly
lower than that for the non-AKI group and was not different
than that for the non-recovery group (Fig. 6). Discrepant
results between the rate of survival and the favourable neu-
rological outcome show the potential and limitation of renal
recovery for its usage as an outcome predictor and treatment
goal. In addition, the dilemma remains that recovery from
AKI might be a significant independent predictor only for
short-term survival of OHCA patients and not for long-term
outcome. This issue should be evaluated in the additional
study by using long-term primary outcome such as survival and
neurological outcome at 6-month or 12-month after OHCA.
A previous retrospective study reported renal recovery as
a potent predictor of survival and favourable neurological
outcome at discharge [4]. Several factors might contribute to
the differences in the results between our study and those of
previous studies. First, although the previous study assessed
the outcomes at different time points according to patients
(e.g., at discharge), the assessment of outcome in our study
was determined at the same time point (30 days after OHCA).
Second, although the development of AKI and renal recovery
had been determined considering both the serum creatinine
and hourly urine output in both studies, there were limitations
in defining AKI on the basis of hourly urine output in the
retrospective cohort because of incomplete data. While 19%
of AKI was diagnosed by applying hourly urine output criteria
in our study, only 3% of AKI was diagnosed using urine output
criteria in the previous study. This difference might affect the
defining process of AKI and recovery from AKI.
Another interesting result was the difference in the recovery
rate according to the stages of AKI (Fig. 2). Especially, the
recovery rate in the AKI stage 3 was only 17%. It was signifi-
cantly lower than that of the stage 1 or 2 AKI. Recovery from
AKI itself was an independent predictor of survival outcome;
a significantly lower recovery rate of AKI stage 3 could affect
the lower rate of survival at 30 days for theAKI stage 3 (33.3%)
(Fig. 3). A chicken-or-egg question might arise here. The
severity of AKI stage 3 itself might decrease the rate of renal
recovery because a more severe AKI was a risk factor for non-
recovery [3, 17]. However, a lower recovery rate in stage 3
AKI might be a reason for high mortality. Further research
will be needed for investigating the role of renal recovery for
different stages of AKI and clinical outcomes.
5. Limitations
Our study has several limitations. First, the predictor of
renal recovery could not be determined because the number
of participants was small. Another clinical trial, including a
large number of patients, will be needed for determining the
factors associated with renal recovery. Second, although ‘re-
covery from AKI’ was defined as the absence of AKI criteria,
using this definition might underestimate or overestimate renal
recovery [17]. New biomarkers for accurate estimation of renal
recovery will be needed for overcoming this limitation. Third,
a significant number of patients (n = 150) were excluded from
the screening process because they were not treated with TTM.
Although TTM had been regarded as a standard treatment after
cardiac arrest, it was not provided to some patients because of
several reasons, including relative contraindications of TTM
and financial issues [4]. Additionally, a relatively large num-
ber of patients (n = 86) were excluded because their legal
surrogates refused to participate in the study. As a result, there
was a possibility in the occurrence of selection bias. Although
this study was not an interventional but an observational study,
legal surrogates hesitated to provide written informed consent.
Therefore, the possibility of selection bias exists.
6. Conclusions
Recovery from AKI was an independent predictor of survival
at 30 days only after OHCA who were treated by TTM.
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